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Abstract
Background: Consequences of hyperoxemia, such as acute lung injury, atelectasis, and reduced bacterial clearance,
might promote ventilator-associated pneumonia (VAP). The aim of our study was to determine the relationship
between hyperoxemia and VAP.
Methods: This retrospective observational study was performed in a 30-bed mixed ICU. All patients receiving
invasive mechanical ventilation for more than 48 hours were eligible. VAP was defined using clinical, radiologic, and
quantitative microbiological criteria. Hyperoxemia was defined as PaO2 > 120 mmHg. All data, except those related
to hyperoxemia, were prospectively collected. Risk factors for VAP were determined using univariate and
multivariate analysis.
Results: VAP was diagnosed in 141 of the 503 enrolled patients (28 %). The incidence rate of VAP was 14.7 per
1000 ventilator days. Hyperoxemia at intensive care unit admission (67 % vs 53 %, OR = 1.8, 95 % CI (1.2, 29), p <0.
05) and number of days spent with hyperoxemia were significantly more frequent in patients with VAP, compared
with those with no VAP. Multivariate analysis identified number of days spent with hyperoxemia (OR = 1.1, 95 % CI
(1.04, 1.2) per day, p = 0.004), simplified acute physiology score (SAPS) II (OR = 1.01, 95 % CI (1.002, 1.024) per point,
p < 0 .05), red blood cell transfusion (OR = 1.8, 95 % CI (1.2, 2.7), p = 0.01), and proton pomp inhibitor use (OR = 1.9,
95 % CI (1.03, 1.2), p < 0.05) as independent risk factors for VAP. Other multiple regression models also identified
hyperoxemia at ICU admission (OR = 1.89, 95 % CI (1.23, 2.89), p = 0.004), and percentage of days with hyperoxemia
(OR = 2.2, 95 % CI (1.08, 4.48), p = 0.029) as independent risk factors for VAP.
Conclusion: Hyperoxemia is independently associated with VAP. Further studies are required to confirm our results.
Keywords: Arterial oxygen tension, Ventilator-associated pneumonia, Critical care, Prevention, Outcome,
Hyperoxemia, Hyperoxia
Background
Hyperoxemia is common in mechanically ventilated
critically ill patients. Its incidence ranges from 16–50 % in
this population [1–5]. Liberal oxygen therapy is supposed
to prevent hypoxia and improve the oxygen supply to the
different affected organs. However, evidence from several
recent studies suggests that hyperoxemia is probably not
safe. Hyperoxemia is responsible for vasoconstriction and
decreased cardiac output, resulting in reduced blood flow
and oxygen transport [6, 7]. A negative impact of
hyperoxemia on mortality is also reported in different pa-
tient populations, such as patients undergoing resuscitation
from cardiac arrest [8], patients with acute ischemic stroke
[5], and patients with ST-segment elevation [9]. In mech-
anically ventilated patients, the relationship between mor-
tality and hyperoxemia is still controversial [10–12]. The
definition of hyperoxemia, measurement methods, and pa-
tient population are very heterogeneous in the available
studies, making it difficult to interpret the results.
Exposure to hyperoxia is responsible for hyperoxic
acute lung injury (HALI). Pulmonary edema, hyaline
membrane formation, pulmonary arteriole thickening,
and alteration in the ventilation/perfusion fraction are
the main mechanisms described in HALI [13, 14]. In
addition, denitrogenation phenomena, and inhibition of
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surfactant production are observed at high levels of in-
spired oxygen fraction (FiO2), promoting expiratory col-
lapse and atelectasis [15, 16]. Hyperoxia also impairs
mucociliary clearance and the antimicrobial action cap-
acity of macrophages and immune cells [17]. Acute lung
injury, atelectasis, and reduced bacterial clearance are
well-known risk factors for VAP [18–20].
VAP is the most common ICU-acquired infection, and is
associated with high mortality, duration of mechanical ven-
tilation, and cost [21]. Therefore, prevention of VAP is a
key issue in critically ill patients. Understanding the patho-
physiology of VAP, and identification of risk factors are
important in order to improve preventive strategies [22].
Previous animal studies strongly suggest a relationship
between hyperoxemia and VAP. However, in spite of the
obvious potential link between hyperoxemia and VAP, to
our knowledge no study to date has evaluated the rela-
tionship between these two conditions. Therefore, we
conducted this retrospective observational study to
determine whether hyperoxemia is a risk factor for VAP.
Methods
Study characteristics
This retrospective observational study was performed in
a 30-bed mixed ICU, located in the University Hospital
of Lille, France. All data, except blood gases results, were
collected prospectively during an 18-month period.
Because of the observational design, and in accordance
with French law, written informed consent was not
required. The local institutional review board (Comité
de Protection des Personnes Nord-Ouest IV) approved
the study. All patients requiring invasive mechanical
ventilation for more than 48 h, during an 18-month
period, were eligible. The only exclusion criterion was
duration of mechanical ventilation for ≤48 h.
Definitions
VAP was defined as the presence of new or progressive
pulmonary infiltrate, and at least two of the following
criteria: (1) fever (body temperature ≥38 °C) or
hypothermia (<36 °C); (2) leukocytosis (>12 × 109/L leu-
kocytes) or leukopenia (<3.5 × 109/L); and (3) purulent
respiratory secretions. Microbiological confirmation was
required in all patients (positive bronchoalveolar lavage
≥104 colony-forming units (cfu)/mL, or positive tracheal
aspirate ≥105 cfu/mL) [23]. Only first episodes of VAP
diagnosed >48 h after starting mechanical ventilation
were taken into account. Early-onset episodes were
defined as VAP diagnosed <5 days after starting mechan-
ical ventilation, and late-onset episodes as VAP
diagnosed ≥5 days after mechanical ventilation. Hyper-
oxemia was defined as arterial oxygen tension (PaO2)
>120 mmHg. Arterial blood gases were analyzed on a
daily basis, and each day with at least one PaO2 value
>120 mmHg (>16 kPa) was considered as a day with
hyperoxemia.
The following microorganisms were defined as
multidrug-resistant bacteria: ceftazidime or imipenem-
resistant Pseudomonas aeruginosa, Acinetobacter bau-
mannii, Stenotrophomonas maltophilia, β-lactamase-
producing Gram-negative bacilli and methicillin-resistant
Staphylococcus aureus. Prior antibiotic use was defined as
antimicrobial treatment during the 3 months preceding
ICU admission. Immunosuppression was defined by the
presence of neutropenia (neutrophils <500/μL), active
solid or hematological malignancy, long-term corticoster-
oid therapy (≥1 mg/kg/d for >1 month), or HIV infection
(CD4 < 50/μL during the previous 6 months).
Study patients
A VAP prevention strategy was routinely used during
the study period. The ventilator circuit was not changed
routinely. In all patients, a heat-moisture exchanger was
positioned between the Y piece and the patient. These
exchangers were changed every 48 h or more frequently
if visibly soiled. Sedation and weaning were based on a
written protocol. A minimal positive end-expiratory
pressure of 5 cm H2O was used in all patients. Selective
digestive decontamination and subglottic secretion
drainage were not used. The oral cavity was cleaned with
chlorehexidine three times daily. Cuff pressure was
measured and adjusted (25 cm H2O) by nurses thrice a
day. Tracheal suctioning was routinely performed by
nurses, using an open tracheal suction system. Patients
remained in the semi-recumbent position, and received
enteral nutrition based on a written protocol.
Antibiotic treatment for patients with suspected VAP
was based on American Thoracic Society/Infectious
Diseases Society of America (ATS/IDSA) guidelines [23].
Antibiotic treatment for other infections was based on
written local guidelines adapted from international and
national guidelines. Stress ulcer prophylaxis was not
routinely used.
Data collection
All data were prospectively recorded, except blood gases
results. The following characteristics were recorded at
ICU admission: age, male gender, severity of illness
based on simplified acute physiology score (SAPS) II,
logistic organ dysfunction (LOD) score, and McCabe
score; comorbidities (diabetes, chronic obstructive pul-
monary disease (COPD), chronic heart failure, cirrhosis,
chronic renal failure requiring dialysis, or immunosup-
pression), location before ICU admission, admission
category (medical or surgical), reason for ICU admission
(acute exacerbation of COPD, acute respiratory distress
syndrome, pneumonia, congestive heart failure,
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neurologic failure, poisoning, shock [24], cellulitis, or in-
fection), and prior antibiotic use.
During the ICU stay data were collected on tracheos-
tomy, red blood cell transfusion, sedation, stress ulcer
prophylaxis, use of neuromuscular-blocking agents,
number of days with PaO2 > 120 mmHg, percentage of
days with PaO2 > 120 mmHg, occurrence of VAP,
duration of mechanical ventilation, and ICU mortality.
Statistical analysis
SPSS software (SPSS, Chicago, IL, USA) was used for
data analysis. Categorical variables were described as fre-
quency (%). The distribution of continuous variables was
tested for normality. Normally distributed and skewed
continuous variables were described as mean ± standard
deviation (SD) or as median and interquartile range
(IQR), respectively. All p values were two-tailed. Differ-
ences were considered significant if p values were <0.05.
In order to determine factors associated with VAP,
patients with VAP were compared with those without
VAP using bivariate and multivariate analyses. The chi-
square (χ2) test or Fischer’s exact test was used to com-
pare qualitative variables, as appropriate. Student’s t test
or the Mann-Whitney U test was used to compare nor-
mally distributed, and skewed continuous variables,
respectively. Potential interactions were tested, and the
Hosmer-Lemeshow goodness-of-fit was calculated. The
odds ratio (OR) and 95 % confidence interval (CI) were
calculated for all significant variables in univariate ana-
lysis and in multivariate analysis. Exposure to potential
risk factors for VAP was taken into account until the
occurrence of VAP, or until ICU discharge in patients
with and without VAP, respectively.
Because of obvious interaction between hyperoxemia
at ICU admission, number of days with hyperoxemia,
and percentage of days with hyperoxemia, three different
models of multivariate analysis were used. Each of these
models included all variables with p values <0.1 on
univariate analysis, and hyperoxemia at ICU admission,
number of days with hyperoxemia, or percentage of days
with hyperoxemia. Further, univariable and multivariable
Cox proportional hazard models were used to determine
risk factors for VAP. All variables with p values <0.1 in
the univariable model, and hyperoxemia at ICU admis-
sion, or percentage of days with hyperoxemia were
included in the final multivariable models.
Results
Patient characteristics
During the study period 503 patients received mechan-
ical ventilation for >48 h, including 141 patients (28 %)
who had at least one episode of VAP. The incidence rate
of VAP was 14.7 per 1000 ventilator days. Early-onset
and late-onset episodes occurred in 14 (10 %), and 127
(90 %) patients with VAP, respectively. The median
(IQR) duration from starting mechanical ventilation to
diagnosis of VAP was 14 (8, 23) days.
No significant difference was found in age (median (inter-
quartile range) 60 (49, 73) vs 59 (47, 70), years, p = 0.265),
SAPS II (48 (35, 61) vs 48 (36, 62), p = 0.772), LOD score (5
(2, 7) vs 5 (2, 9), p = 0.817), mortality rate (121 out of 289
(41.8 %) vs 82 out of 214 (38.3 %), p = 0.265), duration of
mechanical ventilation (12 (6, 24) vs 13 (7, 26), p = 0.427),
and ICU length of stay (15 (8, 29) vs 18 (10, 31), p = 0.243),
Table 1 Characteristics of study patients at ICU admission
VAP P
Yes No
n = 141 n = 362
Age, years 62 (51.5–74) 57 (46–71) 0.004
Male gender 102 (72) 246 (67) 0.339
SAPS II 53 (41–65) 45 (33–59) <0.001
LOD score 6 (3–9) 5 (2–7) 0.241
McCabe score >2 20 (14) 37 (10) 0.382
Transfer from other wards 96 (68) 216 (60) 0.081
Chronic diseases
Diabetes 16 (11) 62 (17) 0.108
COPD 41 (29) 98 (27) 0.651
Cardiac failure 34 (24) 67 (18) 0.159
Cirrhosis 4 (3) 14 (4) 0.576
Chronic dialysis 2 (1) 10 (3) 0.375
Immunosuppression 38 (27) 78 (22) 0.196
Admission category 0.499
Medical 91 (65) 245 (67)
Surgical 48 (34) 114 (31)
Cause for ICU admission
Acute exacerbation of COPD 16 (11) 46 (12) 0.677
ARDS 22 (15) 38 (10) 0.113
Pneumonia 40 (28) 91 (25) 0.458
Congestive heart failure 5 (3) 9 (2) 0.516
Neurologic failure 16 (11) 50 (13) 0.462
Poisoning 16 (11) 30 (8) 0.285
Shock 64 (45) 111 (30) 0.002a
Cellulitis 10 (7) 48 (13) 0.052
Infection 97 (69) 246 (67) 0.856
Prior antimicrobial treatment 70 (50) 178 (49) 0.924
PaO2 > 120 mmHg 95 (67) 193 (53) 0.004b
aOR = 1.9, 95 % CI (1.3, 2.8); bOR = 1.8, 95 % CI (1.2, 2.7). The results are
expressed in number (%) for categorical variables and in median (IQR) for
quantitative variables. ARDS acute respiratory distress syndrome, COPD,
chronic obstructive pulmonary disease, CI confidence interval, ICU intensive
care unit, LOD logistic organ dysfunction, MV mechanical ventilation, OR odds
ratio, PaO2 arterial oxygen tension, SAPS simplified acute physiology score, VAP
ventilated-associated pneumonia
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between patients with hyperoxemia and those with no
hyperoxemia at ICU admission.
Risk factors for VAP by univariate analysis
At ICU admission, age, SAPS II, LOD score, and percent-
age of patients with shock, or with PaO2 > 120 mmHg
were significantly higher in VAP patients, compared with
those with no VAP (Table 1).
During the ICU stay, the percentage of patients with
stress ulcer prophylaxis, red blood cell transfusion, or
sedation was significantly higher in patients with VAP
compared to patients without VAP. Number of days with
hyperoxemia was also significantly higher in patients
with VAP compared to patients without VAP (Table 2).
The percentage of patients with VAP, based on the num-
ber of days with hyperoxemia is presented in Fig. 1.
Microbiological results
VAP was polymicrobial in 8 patients (6 %), and related
to multidrug resistant (MDR) bacteria in 58 patients
(41 %). Gram-negative bacteria represented 78 % of all
bacteria, and were identified in 82 % of patients with
VAP. P. aeruginosa (34 %), S. aureus (11 %), and A. bau-
mannii (9 %) were the most common bacteria in
patients with VAP. MDR bacteria represented 41 % of all
bacteria (58 out of 149) (Table 3).
Risk factors for VAP by multivariate analysis
Because of significant (p < 0.05) interactions between
hyperoxemia at ICU admission, number of days with
hyperoxemia, and percentage of days with hyperoxemia,
three different logistic regression models were used with
only one of these factors in each model. No other signifi-
cant (p > 0.1) interactions were found between other
factors introduced in the multivariable models.
The results of the three logistic regression models are
presented in Table 4. Number of days with hyperoxemia,
hyperoxemia at ICU admission, and percentage of days
with hyperoxemia were independently associated with
VAP in models 1, 2, and 3, respectively.
Risk factors for VAP by univariate and multivariate Cox
proportional hazards models
Hyperoxemia at ICU admission and percentage of days
with hyperoxemia were independently associated with
VAP, using two different Cox proportional hazards
models (Table 5).
Discussion
Our results suggest that hyperoxemia is an independent
risk factor for VAP. To our knowledge, our study is the
first to evaluate the relationship between hyperoxemia
and VAP. As discussed previously, this result could be
explained by the occurrence of HALI, atelectasis, and
Table 2 Patient characteristics during the ICU stay
VAP P
Yes No
n = 141 n = 362
Stress ulcer prophylaxis 0.002
Proton-pump inhibitor 122 (86) 279 (77)
Sucralfate 9 (6) 46 (13)
No 10 (7) 40 (11)
Tracheostomy 24 (17) 47 (13) 0.243
Red blood cell transfusion 86 (61) 139 (38) <0.001a
Sedation 122 (86) 284 (78) 0.039b
Neuromuscular-blocking agent use 10 (7) 20 (6) 0.505
Mean number of ABG per day 3 (1–6) 2 (1–5) 0.261
Number of days with PaO2 > 120 mmHg 5 (2–7) 3 (1–5) <0.001
Percentage of days with PaO2 > 120 mmHg 0.33 (0.19–0.58) 0.33 (0.14–0.50) 0.282
Duration of MV prior to VAP, days 14 (8–23) 9 (5–17) <0.001
Total duration of MV, days 30 (17–43) 9 (5–17) <0.001
Length of ICU stay, days 34 (19–45.5) 12 (7–21) <0.001
ICU mortality 73 (52) 130 (35) 0.001c
The results are expressed in number (%) for categorical variables and in median (IQR) for quantitative variables. Exposure to potential risk factors for VAP was
taken into account until VAP occurrence, or until ICU discharge in patients with and without VAP, respectively. aOR = 2.5 (1.7, 3.7); bOR = 1.8 (1.02, 3.0); cOR = 1.9
(1.3, 2.8)
VAP ventilator-associated pneumonia, CI confidence interval, ICU intensive care unit, OR odds ratio, ABG arterial blood gas, PaO2 arterial oxygen tension, MV
mechanical ventilation
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reduced mucocilliary clearance in patients with
hyperoxemia [25–28]. Previous studies reported high
rates of VAP in patients with acute respiratory distress
syndrome [18, 29]. Further, positive expiratory pressure
was identified as a preventive measure against VAP [30],
by reducing atelectasis in mechanically ventilated patients
[31]. Excess oxygen administration could damage tissues
through the production of reactive oxygen species (ROS).
In excessive concentrations, ROS-mediated stress can lead
to cellular necrosis and apoptosis [32]. Therefore, the
process of oxidative stress might promote the develop-
ment of multi-organ failure [33]. In addition, oxidative
stress is responsible for direct damage to biological mole-
cules (DNA oxidation, proteins, lipids and carbohydrates)
and indirect injury through the release of cytotoxic
products and mutagenic effects of lipid oxidation [16].
Recent animal studies support the role of hyperoxemia
in the pathogenesis of VAP. Entezari and colleagues
demonstrated that prolonged exposure to hyperoxia can
compromise the ability of macrophages, an essential part
of innate immunity, to phagocytose P. aeruginosa [34].
The same group of investigators reported that hyperoxia
results in elevated concentrations of high mobility group
box-1 (HMGB1), and mortality in mice infected with P.
aeruginosa [17]. Treatment of these animals with a neu-
tralizing anti-HMGB1 monoclonal antibody allowed a
reduction in bacterial counts, injury, and numbers of
neutrophils in the lungs, and an increase in leucocyte
phagocytic activity compared with control animals. An-
other recent animal study suggests that hyperoxia
increases mortality in mice with A. baumannii pneumo-
nia, and that procysteine improves survival by increasing
the phagocytic activity of alveolar macrophages [35].
The incidence of multidrug resistant bacteria was rela-
tively high in patients with VAP. This could be explained
by the high percentage of patients with late-onset VAP,
prior antibiotic treatment, or COPD, and the high
Fig. 1 Distribution of ventilator-associated pneumonia (VAP) episodes based on number of days with hyperoxemia
Table 3 Microorganisms isolated in patients with ventilator-
associated pneumonia
Microorganisms Number (%)
Gram-negative bacilli 116 (82)
Pseudomonas aeruginosa 48 (34)
Escherichia Coli 14 (10)
Acinetobacter baumannii 13 (9)
Enterobacter sp. 13 (9)
Klebsiella sp. 8 (5)
Proteus mirabilis 6 (4)
Serratia sp. 5 (3.5)
Stenotrophomonas maltophilia 4 (2.8)
Others 5 (3.5)
Gram-positive cocci 33 (23)
Methicillin-resistant Staphylococcus aureus 11 (7.8)
Staphylococcus epidermidis 7 (5)
Methicillin-sensitive Staphylococcus aureus 5 (3.5)
Enterococcus sp. 5 (3.5)
Streptococcus pneumoniae 5 (3.3)
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severity of illness at ICU admission. All these factors
were previously identified as independent risk factors for
multidrug resistant bacteria [36–39].
Our study has several limitations. First, it was a retro-
spective study performed in a single center. Therefore,
our results could not be generalized and further pro-
spective multicenter studies are needed to confirm these
findings. However, all data, except those related to
hyperoxemia, were prospectively collected. Second, the
cutoff used for hyperoxemia (>120 mmHg) was selected
based on the current literature [12, 40, 41]. For example,
normal PaO2 is defined by the British Thoracic Society
as between 90 and 110 mmHg for patients under
70 years of age and according to the sea level [42].
However, other studies used a different cutoff (i.e., to
PaO2 ≥ 300 mmHg) to define hyperoxemia [8, 43, 44].
Because a day with at least one PaO2 value
>120 mmHg was considered as a day with hyperoxe-
mia, our definition of hyperoxemia might have over-
estimated the time period of hyperoxemia.
Continuous control of pulse oximetry could be more
appropriate to accurately determine time spent with
hyperoxemia. Third, no information was collected on
PaO2, FiO2, or positive end-expiratory (PEEP) values.
Some risk factors, such as head-of-bed elevation and
under-inflation of tracheal cuff, were not evaluated in
this study. Finally, because of the retrospective design,
exploratory investigations, such as measurement of
ROS or evaluation of immune function could not be
performed.
Two recent small studies [2, 5], one before-after and
one randomized controlled study, suggested that a con-
servative oxygenation strategy might be safe in intubated
critically ill patients, compared with a liberal strategy.
However, none of these studies evaluated the impact of
oxygenation strategy on VAP incidence. Further large
randomized controlled trials are required to confirm
these data, and to determine the impact of oxygenation
strategy on VAP incidence.
Table 5 Risk factors for ventilator-associated pneumonia by Cox proportional hazards model
Variable Univariate analysis Multivariate analysis (model 1) Multivariate analysis (model 2)
HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
At ICU admission
LOD score 1.04 (1.01, 1.09) 0.044 - 0.922 - 0.138
Transfer from other wards 0.65 (0.45, 0.93) 0.018 - 0.356 - 0.952
Prior antibiotic treatment 0.67 (0.48, 0.94) 0.021 - 0.483 - 0.184
Neurologic failure 1.82 (1.07, 3.09) 0.027 - 0.111 - 0.197
Poisoning 3.24 (1.9, 5.51) <0.001 2.49 (1.31, 4.72) 0.005 2.16 (1.14, 4.09) 0.018
COPD 0.55 (0.37, 0.89) 0.003 - 0.063 - 0.065
McCabe score >2 0.76 (0.59, 0.99) 0.042 - 0.169 0.726
PaO2 > 120 mmHg 1.58 (1.11, 2.25) 0.011 NA NA 1.68 (1.16, 2.42) 0.006
During ICU stay
Percentage of days with PaO2 > 120 mmHg 5.67 (3.15, 10.20) <0.001 6.23 (3.26, 11.9) <0.001 NA NA
HR hazard ratio, LOD logistic organ dysfunction, COPD chronic obstructive pulmonary disease, NA not applicable. P > 0.1 by univariate analysis for: age, male
gender, simplified acute physiology score II, diabetes, cardiac failure, cirrhosis, chronic dialysis, immunosuppression, all causes of ICU admission except neurologic
failure, stress ulcer prophylaxis, tracheostomy, red blood cell transfusion, sedation, and neuromuscular-blocking agent use
Table 4 Factors associated with ventilator-associated pneumo-
nia by multivariate analysis
Variables P OR (95 % CI)
Model 1
SAPS II 0.019 1.01 (1.00, 1.02)*
Red blood cell transfusion 0.009 1.75 (1.14, 2.70)
Proton pump inhibitor use 0.040 1.86 (1.03, 3.39)
Number of days with hyperoxemia 0.001 1.10 (1.04, 1.16)**
Model 2
SAPS II 0.017 1.01 (1.00, 1.02)*
Red blood cell transfusion 0.009 1.79 (1.16, 2.78)
Proton pump inhibitor use 0.031 1.92 (1.06, 3.50)
MV duration prior to VAP 0.012 1.10 (1.01, 1.04)**
Hyperoxemia at ICU admission 0.004 1.89 (1.23, 2.89)
Model 3
Red blood cell transfusion 0.018 1.71 (1.10, 2.65)
Proton pump inhibitor use 0.017 2.10 (1.14, 3.79)
MV duration prior to VAP 0.005 1.03 (1.01, 1.04)*
Percentage of days with hyperoxemia 0.029 2.20 (1.08, 4.48)**
SAPS simplified acute physiology score; MV mechanical ventilation, VAP
ventilator-associated pneumonia. Model 1: *per point of SAPS II, **per day with
hyperoxemia; Hosmer-Lemshow goodness-of-fit, p = 0.62. Other non-significant
variables included in the model: transfer from other wards, shock, sedation,
and duration of MV prior to VAP. Model 2: *per point of SAPS II, **per day of
mechanical ventilation; Hosmer-Lemshow goodness-of-fit, p = 0.81. Other non-
significant variables included in the model: transfer from other wards, shock,
and sedation. Model 3: *per day of mechanical ventilation, **per centile of
days with hyperoxemia; Hosmer-Lemshow goodness-of-fit, p = 0.78. Other
non-significant variables included in the model: SAPS II, transfer from other
wards, shock, and sedation
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Conclusion
Our results suggest a link between hyperoxemia and
VAP. However, further large prospective studies are re-
quired to confirm these findings and to evaluate the im-
pact of a conservative oxygen strategy vs a conventional
strategy, on the incidence of VAP.
Key messages
 Hyperoxemia is independently associated with
ventilator-associated pneumonia
 This association could be explained by the
consequences of hyperoxemia, including acute lung
injury, atelectasis, and reduced bacterial clearance
 Further large multicenter studies are required to
confirm our results
Abbreviations
ARDS, acute respiratory distress syndrome; cfu, colony-forming units; CI, con-
fidence interval; COPD, chronic obstructive pulmonary disease; FiO2, inspired
oxygen fraction; HALI, hyperoxic acute lung injury; ICU, intensive care unit;
LOD, logistic organ dysfunction; MDR, multidrug resistant; OR, odds ratio;
PaO, arterial oxygen tension; ROS, reactive oxygen species; SAPS, simplified
acute physiology score; VAP, ventilated-associated pneumonia
Authors’ contributions
SN, SS, KJ, and FW designed the study. SS, KJ, GL, and EJ collected the data.
SS, KJ, and SN wrote the manuscript. All authors made substantial
contribution. All authors read and approved the final version of the
manuscript.
Competing interests
SN is involved with Bayer, Basilea, and Medtrocic (advisory board, and
lecture); all other authors have no competing interests.
Author details
1CHU Lille, Centre de Réanimation, F-59000 Lille, France. 2CHU Lille, Centre
de Biologie et de Pathologie, F-59000 Lille, France. 3Univ Lille, Faculté de
Médecine, F-59000 Lille, France.
Received: 28 January 2016 Accepted: 1 June 2016
References
1. Suzuki S, Eastwood GM, Peck L, Glassford NJ, Bellomo R. Current oxygen
management in mechanically ventilated patients: a prospective
observational cohort study. J Crit Care. 2013;28:647–54.
2. Suzuki S, Eastwood GM, Glassford NJ, Peck L, Young H, Garcia-Alvarez M,
Schneider AG, Bellomo R. Conservative oxygen therapy in mechanically
ventilated patients: a pilot before-and-after trial. Crit Care Med. 2014;42:
1414–22.
3. Rachmale S, Li G, Wilson G, Malinchoc M, Gajic O. Practice of excessive
F(IO(2)) and effect on pulmonary outcomes in mechanically ventilated
patients with acute lung injury. Respir Care. 2012;57:1887–93.
4. Helmerhorst HJF, Schultz MJ, van der Voort PHJ, Bosman RJ, Juffermans NP,
de Wilde RBP, van den Akker-van Marle ME, van Bodegom-Vos L, de Vries
M, Eslami S, de Keizer NF, Abu-Hanna A, van Westerloo DJ, de Jonge E.
Effectiveness and clinical outcomes of a two-step implementation of
conservative oxygenation targets in critically ill patients: a before and after
trial. Crit Care Med. 2016;44(3):554-63.
5. Panwar R, Hardie M, Bellomo R, Barrot L, Eastwood GM, Young PJ, Capellier
G, Harrigan PWJ, Bailey M. Conservative versus liberal oxygenation targets
for mechanically ventilated patients, a pilot multicenter randomized
controlled trial. Am J Respir Crit Care Med. 2016;193:43–51.
6. Cornet AD, Kooter AJ, Peters MJL, Smulders YM. The potential harm of
oxygen therapy in medical emergencies. Crit Care. 2013;17:313.
7. Farquhar H, Weatherall M, Wijesinghe M, Perrin K, Ranchord A, Simmonds
M, Beasley R. Systematic review of studies of the effect of hyperoxia on
coronary blood flow. Am Heart J. 2009;158:371–7.
8. Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K,
Parrillo JE, Trzeciak S. Association between arterial hyperoxia following
resuscitation from cardiac arrest and in-hospital mortality. JAMA.
2010;303:2165–71.
9. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, Cameron P,
Barger B, Ellims AH, Taylor AJ, Meredith IT, Kaye DM. AVOID Investigators. Air
versus oxygen in ST-segment-elevation myocardial infarction. Circulation.
2015;131:2143-50.
10. Helmerhorst HJF, Roos-Blom M-J, van Westerloo DJ, de Jonge E. Association
between arterial hyperoxia and outcome in subsets of critical illness: a
systematic review, meta-analysis, and meta-regression of cohort studies. Crit
Care Med. 2015;43:1508–19.
11. Damiani E, Adrario E, Girardis M, Romano R, Pelaia P, Singer M, Donati A.
Arterial hyperoxia and mortality in critically ill patients: a systematic review
and meta-analysis. Crit Care. 2014;18:711.
12. Eastwood G, Bellomo R, Bailey M, Taori G, Pilcher D, Young P, Beasley R.
Arterial oxygen tension and mortality in mechanically ventilated patients.
Intensive Care Med. 2012;38:91–8.
13. Sinclair SE, Altemeier WA, Matute-Bello G, Chi EY. Augmented lung injury
due to interaction between hyperoxia and mechanical ventilation. Crit Care
Med. 2004;32:2496–501.
14. Kallet RH, Matthay MA. Hyperoxic acute lung injury. Respir Care.
2013;58:123–41.
15. Dantzker DR, Wagner PD, West JB. Proceedings: Instability of poorly
ventilated lung units during oxygen breathing. J Physiol. 1974;242:72P.
16. Hafner S, Beloncle F, Koch A, Radermacher P, Asfar P. Hyperoxia in intensive
care, emergency, and peri-operative medicine: Dr. Jekyll or Mr. Hyde? A
2015 update. Ann Intensive Care. 2015;5:42.
17. Patel VS, Sitapara RA, Gore A, Phan B, Sharma L, Sampat V, Li JH, Yang H,
Chavan SS, Wang H, Tracey KJ, Mantell LL. High Mobility Group Box-1
mediates hyperoxia-induced impairment of Pseudomonas aeruginosa
clearance and inflammatory lung injury in mice. Am J Respir Cell Mol Biol.
2013;48:280–7.
18. Forel J-M, Voillet F, Pulina D, Gacouin A, Perrin G, Barrau K, aber S, Arnal J-M,
Fathallah M, Auquier P, Roch A, Azoulay E, Papazian L. Ventilator-associated
pneumonia and ICU mortality in severe ARDS patients ventilated according
to a lung-protective strategy. Crit Care. 2012;16:R65.
19. van Kaam AH, Lachmann RA, Herting E, De Jaegere A, van Iwaarden F,
Noorduyn LA, Kok JH, Haitsma JJ, Lachmann B. Reducing atelectasis
attenuates bacterial growth and translocation in experimental pneumonia.
Am J Respir Crit Care Med. 2004;169:1046–53.
20. Rello J, Lisboa T, Koulenti D. Respiratory infections in patients undergoing
mechanical ventilation. Lancet Respir Med. 2014;2:764–74.
21. Nair GB, Niederman MS. Ventilator-associated pneumonia: present
understanding and ongoing debates. Intensive Care Med. 2014;41:34–48.
22. Nseir S, Martin-Loeches I. In the name of ventilator-associated pneumonia
prevention: lung microbiota blown away by colistin! Eur Respir J. 2015;46:1544–7.
23. Guidelines for the management of adults with hospital-acquired, ventilator-
associated, and healthcare-associated pneumonia. Am J Respir Crit Care
Med. 2005, 171:388–416.
24. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R,
Mebazaa A, Pinsky MR, Teboul JL, Vincent JL, Rhodes A. Consensus on
circulatory shock and hemodynamic monitoring. Task force of the European
Society of Intensive Care Medicine. Intensive Care Med. 2014;40:1795–815.
25. Budinger GRS, Mutlu GM. Balancing the risks and benefits of oxygen
therapy in critically ill adults. Chest. 2013;143:1151–62.
26. Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Annu Rev
Physiol. 1986;48:721–31.
27. Sackner MA, Landa J, Hirsch J, Zapata A. Pulmonary effects of oxygen
breathing. A 6-hour study in normal men. Ann Intern Med.
1975;82:40–3.
28. Fox RB, Hoidal JR, Brown DM, Repine JE. Pulmonary inflammation due to
oxygen toxicity: involvement of chemotactic factors and
polymorphonuclear leukocytes. Am Rev Respir Dis. 1981;123:521–3.
29. Delclaux C, Roupie E, Blot F, Brochard L, Lemaire F, Brun-Buisson C. Lower
respiratory tract colonization and infection during severe acute respiratory
distress syndrome: incidence and diagnosis. Am J Respir Crit Care Med.
1997;156(4 I):1092–8.
Six et al. Critical Care  (2016) 20:195 Page 7 of 8
30. Manzano F, Fernández-Mondéjar E, Colmenero M, Poyatos ME, Rivera R,
Machado J, Catalán I, Artigas A. Positive-end expiratory pressure reduces
incidence of ventilator-associated pneumonia in nonhypoxemic patients.
Crit Care Med. 2008;36:2225–31.
31. Aboab J, Jonson B, Kouatchet A, Taille S, Niklason L, Brochard L. Effect of
inspired oxygen fraction on alveolar derecruitment in acute respiratory
distress syndrome. Intensive Care Med. 2006;32:1979–86.
32. Martin DS, Grocott MPW. Oxygen therapy in critical illness: precise control
of arterial oxygenation and permissive hypoxemia. Crit Care Med.
2013;41:423–32.
33. Motoyama T, Okamoto K, Kukita I, Hamaguchi M, Kinoshita Y, Ogawa H.
Possible role of increased oxidant stress in multiple organ failure after
systemic inflammatory response syndrome. Crit Care Med. 2003;31:1048–52.
34. Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J, Wang H, Yang
H, Sharma L, Phan BD, Javdan M, Chavan SS, Miller EJ, Tracey KJ, Mantell LL.
Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial
clearance and protects against Pseudomonas Aeruginosa pneumonia in
cystic fibrosis. Mol Med. 2012;18:477–85.
35. Saito K, Kimura S, Saga T, Misonoo Y, Yoshizawa S, Akasaka Y, Ishii T,
Kuwano K, Yamaguchi K, Tateda K. Protective effect of procysteine on
Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob
Chemother. 2013;68:2305–10.
36. Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M,
Onimus T, Saulnier F, Mathieu D, Durocher A. First-generation
fluoroquinolone use and subsequent emergence of multiple drug-resistant
bacteria in the intensive care unit. Crit Care Med. 2005;33:283–9.
37. Nseir S, Hoel J, Grailles G, Soury-Lavergne A, Di Pompeo C, Mathieu D,
Durocher A. Remifentanil discontinuation and subsequent intensive care
unit-acquired infection: a cohort study. Crit Care. 2009;13:R60.
38. Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, Torres A,
Niederman MS, Rello J. Potentially resistant microorganisms in intubated
patients with hospital-acquired pneumonia: The interaction of ecology,
shock and risk factors. Intensive Care Med. 2013;39:672–81.
39. Luna CM, Sarquis S, Niederman MS, Sosa FA, Otaola M, Bailleau N, Vay C a,
Famiglietti A, Irrazabal C, Capdevila A a. Is a strategy based on routine
endotracheal cultures the best way to prescribe antibiotics in ventilator-
associated pneumonia? Chest. 2013;144:63–71.
40. Itagaki T, Nakano Y, Okuda N, Izawa M, Onodera M, Imanaka H, Nishimura
M. Hyperoxemia in mechanically ventilated, critically ill subjects: incidence
and related factors. Respir Care. 2015;60:335–40.
41. de Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PHJ,
Bosman RJ, de Waal RAL, Wesselink R, de Keizer NF. Association between
administered oxygen, arterial partial oxygen pressure and mortality in
mechanically ventilated intensive care unit patients. Crit Care. 2008;12:R156.
42. O’Driscoll BR, Howard LS, Bucknall C, Welham SA, Davison AG. British
Thoracic Society emergency oxygen audits. Thorax. 2011;66:734–5.
43. Bellomo R, Bailey M, Eastwood GM, Nichol A, Pilcher D, Hart GK, Reade MC,
Egi M, Cooper DJ. Arterial hyperoxia and in-hospital mortality after
resuscitation from cardiac arrest. Crit Care. 2011;15:R90.
44. Rincon F, Kang J, Maltenfort M, Vibbert M, Urtecho J, Athar MK, Jallo J,
Pineda CC, Tzeng D, McBride W, Bell R. Association between hyperoxia and
mortality after stroke: a multicenter cohort study. Crit Care Med.
2014;42:387–96.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Six et al. Critical Care  (2016) 20:195 Page 8 of 8
